# INM earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/INM) · [Earnings tab](https://www.lopjlb.com/stock/INM?tab=earnings)

Updated: 2026-09-23T06:05:42

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarterly calls the company moved from early cash‑runway pressure and regulatory uncertainty around CBN to a more funded position after a $12.5 M financing and an $11 M private placement, culminating in the integration of the BayMedica acquisition. Clinical execution accelerated: Phase‑I enrollments and readouts for INM‑755 were completed by 2021 Q2, and Phase‑II filings and the European EB trial progressed through 2022. Manufacturing scale‑up on the IntegraSyn platform showed steady yield improvements (2 g/L) and moved toward GMP‑ready batches, though a global starting‑material shortage introduced a slip in the 1 kg batch target. Demand signals shifted from early strong clinician interest to later ambiguous market appetite, reflected in weak product sales and heightened market‑demand uncertainty. COVID‑related site shutdowns caused early enrollment and GMP delays but their impact lessened over time. Persistent fears—regulatory timing, funding needs, enrollment bottlenecks, manufacturing scale‑up, and supply‑chain constraints—remained across calls, while new concerns about competitive pressure and a tougher biotech financing environment emerged in 2022.

## Latest CallCard · Q4

InMed navigated macro headwinds, advanced its Phase 2 EB trial with enrollment on track for 2022 completion, progressed preclinical glaucoma work, saw weak demand for rare‑cannabinoid products, and cut costs while securing new financing.

**Guidance:** maintained — Management outlined expected data readout Q1 2023, IND filing H1 2024 and candidate selection Q2 2023 without raising or lowering guidance

**Tone:** mgmt 0.5 · Q&A pressure 0.4 · divergence 0.2

Prepared remarks highlighted navigating headwinds, positive momentum and upcoming milestones

### Demand visibility

Demand for rare‑cannabinoid products remains uncertain

Recession, immature market and pricing pressure have slowed revenue growth and led to reduced commercial effort for BayMedica

### Margins / costs

Significant cost‑saving measures implemented

~25% workforce reduction, voluntary salary cuts, no performance bonuses and expected 30% HR expense savings on an annualized basis

### Capital allocation

Capital focused on pharma R&D and balance‑sheet strengthening

Two financings ($5M in June, $6M in September), share consolidation, and reduced spend on BayMedica commercial activities

### Milestones

- **INM-755 Phase 2 EB trial** [on_track]: Nine sites active, 9 patients enrolled, adolescent enrollment started; enrollment expected to complete 2022 with data readout Q1 2023
- **INM-088 glaucoma program** [on_track]: Pre‑IND discussions completed; IND filing targeted for H1 2024
- **Neurodegenerative cannabinoid analog patent** [new]: International patent filed Nov 2022; screening has yielded promising analog candidates
- **BayMedica commercial operations** [at_risk]: Demand slower than anticipated; company reducing commercial effort and converting inventory
- **Cost‑saving initiative** [delivered]: Headcount cut ~25%, salary reductions and no bonuses achieved expected 30% HR expense savings

### Fears / risks

- **Capital market risk**: Biotech financing environment remains challenging, requiring ongoing fundraises
- **Market demand uncertainty**: Recession and immature health‑wellness market delay revenue from rare cannabinoids
- **Clinical enrollment risk**: Trial design requires two symptom areas, potentially slowing patient enrollment
- **Regulatory risk**: IND filing for INM-088 depends on successful preclinical studies and FDA acceptance
- **Competitive risk**: Other companies pursuing cannabinoid therapies could limit market share
- **Economic recession**: Macro‑economic pressures affect investor sentiment and consumer spending
- **Impairment risk**: Intangible asset and goodwill impairment recorded for BayMedica segment
- **Execution risk**: Cost reductions and organizational changes may impact operational capacity

### Key quotes

> “InMed has managed to navigate these headwinds and gain positive momentum across our operations and continued to advance our preclinical and clinical programs”

> “The first adolescent patient with EB has been enrolled into the clinical trial and has completed treatment at the clinical site in Greece during the summer”

> “demand for rare cannabinoids unfortunately not materialized as quickly as we anticipated, resulting in slower than expected revenue growth”

> “in the last quarter, we were an all-in run rate of around $900,000 a month, and we expect to be moving down to about $700,000 a month” — Brenda Edwards

> “The primary readout for Phase 1/2 will be, of course, safety being the first, and IOP reduction in the secondary readout for that 1/2 trial”

## Quarter one-liners

- **2022 Q4:** InMed navigated macro headwinds, advanced its Phase 2 EB trial with enrollment on track for 2022 completion, progressed preclinical glaucoma work, saw weak demand for rare‑cannabinoid products, and cut costs while securing new financing.
- **2022 Q2:** InMed reports integration of its BayMedica acquisition, launches new rare cannabinoid products, starts Phase 2 trial for INM-755, and outlines upcoming product launches while noting COVID‑related supply and enrollment delays.
- **2021 Q4:** InMed highlighted a near‑term BayMedica acquisition, improved IntegraSyn yields, upcoming Phase 2 EB trial, but noted a supply‑chain issue that could delay a 1 kg batch and pending IND filing in late 2022.
- **2021 Q3:** InMed reported European Phase 2 filing progress for INM-755, a 2 g/L yield milestone for IntegraSyn with scale‑up plans, preclinical work on INM-088, a TSX delisting, cash of $9.5 M and a functional‑currency shift to USD.
- **2021 Q2:** InMed Q2 2021 call highlighted successful $12.5M financing, completion of two Phase I trials for INM-755, a licensing deal for INM-088 delivery, progress on IntegraSyn, and modest COVID‑related timeline impacts while staying on track for Phase II filing.
- **2020 Q4:** InMed advanced INM-755 into a second Phase‑1 trial and progressed INM-088 preclinical work while scaling its IntegraSyn cannabinoid platform, but COVID‑related site shutdowns and financing timing pushed some trial filings and GMP readiness into Q1 2021, with guidance to report Phase‑1 results by yea
- **2020 Q3:** InMed reports progress on INM-755 and INM-088 programs with minimal COVID‑19 impact, expects up to two‑month delay to milestones and maintains cash runway into 2021.
- **2020 Q2:** InMed reported progress on its CBN‑based INM‑755 Phase I trial, outlined upcoming milestones for INM‑088, highlighted biosynthesis cost goals and discussed funding options while noting cash runway to Q4 2020.

## Theme arcs

- **Regulatory uncertainty** (stable): Ongoing concerns about CBN scheduling, CTA/IND timing and IND filing for INM‑088 persisted throughout all calls.
- **Funding and cash runway** (improving): Initial cash runway limited to Q4 2020; later secured $12.5 M and $11 M financings and completed BayMedica acquisition.
- **Clinical trial progress** (improving): Phase‑I enrollment and results delivered; Phase‑II filings and EB trial enrollment on track by 2022.
- **Manufacturing scale‑up and cost reduction** (improving): IntegraSyn yields rose to 2 g/L, GMP‑ready process achieved, though 1 kg batch delayed by supply‑chain issue.
- **Market demand perception** (deteriorating): Early strong clinician interest gave way to weak product demand and uncertainty about market size.
- **COVID‑19 impact** (improving): Initial site shutdowns caused delays; later quarters reported only minor timeline impacts.
- **Supply‑chain constraints** (deteriorating): Starting‑material shortage in 2021 Q4 and broader pandemic disruptions affected manufacturing and enrollment.
- **Competitive landscape** (new): 2022 Q4 highlighted risk of other firms pursuing cannabinoid therapies.
- **Capital‑market environment** (new): 2022 Q4 noted challenging biotech financing conditions.

## Guidance path

2020 Q2:maintained → 2020 Q3:maintained → 2020 Q4:maintained → 2021 Q2:maintained → 2021 Q3:maintained → 2021 Q4:maintained → 2022 Q2:maintained → 2022 Q4:maintained

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/INM`